» Articles » PMID: 37362415

Measurement and Clinical Usefulness of Bilirubin in Liver Disease

Overview
Journal Adv Lab Med
Publisher De Gruyter
Specialty Biochemistry
Date 2023 Jun 26
PMID 37362415
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated plasma bilirubin levels are a frequent clinical finding. It can be secondary to alterations in any stage of its metabolism: (a) excess bilirubin production (i.e., pathologic hemolysis); (b) impaired liver uptake, with elevation of indirect bilirubin; (c) impaired conjugation, prompted by a defect in the UDP-glucuronosyltransferase; and (d) bile clearance defect, with elevation of direct bilirubin secondary to defects in clearance proteins, or inability of the bile to reach the small bowel through bile ducts. A liver lesion of any cause reduces hepatocyte cell number and may impair the uptake of indirect bilirubin from plasma and diminish direct bilirubin transport and clearance through the bile ducts. Various analytical methods are currently available for measuring bilirubin and its metabolites in serum, urine and feces. Serum bilirubin is determined by (1) diazo transfer reaction, currently, the gold-standard; (2) high-performance liquid chromatography (HPLC); (3) oxidative, enzymatic, and chemical methods; (4) direct spectrophotometry; and (5) transcutaneous methods. Although bilirubin is a well-established marker of liver function, it does not always identify a lesion in this organ. Therefore, for accurate diagnosis, alterations in bilirubin concentrations should be assessed in relation to patient anamnesis, the degree of the alteration, and the pattern of concurrent biochemical alterations.

Citing Articles

The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.

Hardwick J, Song B, Rote P, Leahy C, Lee Y, Wolf A Front Physiol. 2025; 15:1497297.

PMID: 39959811 PMC: 11826315. DOI: 10.3389/fphys.2024.1497297.


Deciphering of differences in gut microbiota and plasma metabolites profile between non-obese and obese Golden Retrievers dogs.

Cai Y, Tang H, Xiang G, Yi H, Zhong J, Xie Z Front Microbiol. 2025; 15():1514633.

PMID: 39845032 PMC: 11751222. DOI: 10.3389/fmicb.2024.1514633.


Electrolyte imbalance and liver function test abnormalities among pregnant women with hyperemesis gravidarum at Wag-himra zone public hospitals, Northeast Ethiopia, 2023: a comparative cross-sectional study.

Worede A, Deress T, Wondifraw H, Fetene G, Berie A Front Med (Lausanne). 2025; 11:1451036.

PMID: 39741505 PMC: 11685153. DOI: 10.3389/fmed.2024.1451036.


Evaluation of hepatoprotective and nephroprotective activities of extract in rats.

Alkandahri M, Sadino A, Abriyani E, Hermanto F, Oktoba Z, Sayoeti M Biomed Rep. 2024; 22(2):24.

PMID: 39720299 PMC: 11668127. DOI: 10.3892/br.2024.1902.


Evolution of Hematobiochemical Profiles in Newly Diagnosed HIV Patients and HIV-TB Co-Infected Patients: Correlation with Immunological and Virological Status.

Khan N, Verma C, Ali Beg M, Kumar S, Kaushik G, Ahmad H Immunotargets Ther. 2024; 13:691-705.

PMID: 39678140 PMC: 11645950. DOI: 10.2147/ITT.S495295.


References
1.
Lopez-Velazquez J, Chavez-Tapia N, Ponciano-Rodriguez G, Sanchez-Valle V, Caldwell S, Uribe M . Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. Ann Hepatol. 2014; 13(1):98-104. View

2.
Fevery J . Bilirubin in clinical practice: a review. Liver Int. 2008; 28(5):592-605. DOI: 10.1111/j.1478-3231.2008.01716.x. View

3.
KUENZLE C, Maier C, Ruttner J . The nature of four bilirubin fractions from serum and of three bilirubin fractions from bile. J Lab Clin Med. 1966; 67(2):294-306. View

4.
McDonagh A, Assisi F . Commercial bilirubin: A trinity of isomers. FEBS Lett. 1971; 18(2):315-317. DOI: 10.1016/0014-5793(71)80475-1. View

5.
Ngashangva L, Bachu V, Goswami P . Development of new methods for determination of bilirubin. J Pharm Biomed Anal. 2018; 162:272-285. DOI: 10.1016/j.jpba.2018.09.034. View